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Highlights: 
 Vastii activation duration is longer during stair descent in people with PFOA. 
 Vastus lateralis onset is earlier for ascent and descent.  
 Soleus onset is earlier during descent. 
 Gluteus maximus activation duration is shorter during stair ascent.  
 Clinical assessment of gluteal and quadriceps function may be important in 
PFOA. 
 
 
1. Introduction: 
 
Knee osteoarthritis (OA) affects up to 25% of people aged 40 to 50 years with 
knee pain [1], and approximately 50% of people over 60 years of age [2]. People with 
knee OA have significantly poorer quality of life compared with age matched, 
healthy controls [3]. There is currently no cure for knee OA and those with end-stage 
disease typically undergo total knee replacement with the number of total knee 
replacement procedures performed yearly expected to increase by 670%, by the 
year 2030 [4].  
 
In people with knee pain or radiographic OA, 50% have patellofemoral (PF) 
involvement [5]. Compared to tibiofemoral (TF) OA, isolated PFOA is associated with 
greater pain and functional limitations during activities of daily living [6]. Further the 
presence of isolated symptomatic PFOA is a marker for subsequent development 
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and progression of TFOA [7]. Despite the prevalence and impact of PFOA, few 
studies have considered biomechanical contributors to its etiology, and there 
remains limited evidence for treatments to target specific biomechanical 
impairments. 
 
Individuals with PFOA regularly report discomfort during activities that 
involve knee flexion, such as prolonged sitting, squatting, and stair ambulation [8]. 
Not surprisingly, individuals with PFOA ascend and descend stairs with altered 
kinematics (e.g. increased anterior pelvic tilt, smaller knee flexion angles) and lower 
PF joint forces compared to age- and sex-matched controls [9]. However, muscle 
activation strategies and dynamic stability during stair ambulation have not been 
described in this population.  
 
If individuals with PFOA have altered activation of lower limb muscles during 
tasks such as stair ambulation, optimizing muscle recruitment strategies may be a 
potential target for clinical interventions aimed at improving pain and function, 
potentially delaying or reducing disease progression. 
 
The purpose of this study was to determine if lower limb neuromotor control 
is different in individuals with PFOA compared to asymptomatic controls when 
performing stair ascent and descent tasks.  
 
2. Methods 
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Study design: Cross-sectional 
 
Participant recruitment: Participants with PFOA were recruited as part of a 
pilot randomized controlled trial (RCT) investigating the effects of footwear and foot 
orthoses on pain and function. Full details of the recruitment procedures have been 
published elsewhere [10]. Inclusion and exclusion criteria are described in Table 1. 
Briefly, the first 23 people with PFOA recruited into the RCT were invited to have 
electromyographic recordings taken of 14 lower limb muscles while stepping up and 
down on a single step. All participants provided written informed consent. This study 
was approved by The University of Queensland’s Medical Research Ethics Committee 
(approval number: 2014000068).  
 
 
 
Insert Table 1  
 
 
 
 
 
Quality of life and physical activity questionnaires: As general measures of 
health status and physical activity levels, participants in both groups were asked to 
complete the EQ-5D questionnaire [11] and the International Physical Activity 
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Questionnaire (IPAQ) [12]. The IPAQ was scored as a continuous measure, expressed 
as metabolic equivalent of task (MET) minutes per week. 
 
Force plate data: A 17cm high platform, with two force plates at the bottom 
(Kistler, Switzerland) and a single force plate on the top (Bertec, Ohio, USA) was used 
to record ground reaction forces during the stepping tasks. Taped markings on the 
force plates were used to standardise starting position (Figure 1A and 1B). Force 
plate data were sampled at 2048Hz using Spike2 software (Cambridge Electronic 
Design Ltd, UK). 
 
Electromyography (EMG): Neuromotor control of the lower limbs was 
assessed during stair ascent and descent tasks. In the PFOA group, approximately 
68% of participants reported bilateral symptoms, thus stepping with the most 
painful side first was chosen as the task of interest. In the control group, stepping 
with the dominant side was chosen [13], equating to ~60% of right limbs being 
tested in both populations (see Table 1). Surface EMG signals were recorded from 
the following muscles: gluteus maximus (GMax), gluteus medius (GMed), medial 
hamstrings (MH), lateral hamstrings (LH), vastus medialis (VM), vastus lateralis (VL), 
medial gastrocnemius (MG), lateral gastrocnemius (LG), and soleus (Sol). All sites 
were shaved, abraded and cleaned with alcohol. Electrode placement was according 
to standardised protocols (Ambu ® BlueSensor bipolar electrodes, inter-electrode 
distance 20mm, www.seniam.org). Electromyographic recordings were acquired 
using a 16 channel TMSi Porti Device (TMSi, Netherlands), sampled at 2048 Hz 
AC
CE
PT
ED
 M
AN
US
CR
IPT
6 
 
(PortiLab, TMSi, Netherlands). The small, portable EMG base-unit, was held by 
participants in front of their abdomen, controlling arm position during the tasks. 
 
Experimental Task: Participants completed 12 repetitions of both the stair 
ascent and descent tasks. A light positioned ~ 1.5 m in front of participants, at 
ground level, indicated when to commence the stepping task. Participants were 
instructed to step immediately in response to the light stimuli. Speed of response 
was not assessed, but if a significant delay in response occurred, or the incorrect 
limb was used to perform the stepping task, the trial was repeated.  
 
For the stair ascent task, participants stood with one foot on each of the 
lower force plates, 6 cm from front of the force plate and 16 cm apart. Participant 
were instructed to step up onto the platform (leading with their test limb), pause to 
regain balance, then step back down on to the bottom force plates. For the stair 
descent task, participants stood with both feet positioned 4cm from the front of the 
top force plate and 16 cm apart.  When indicated by the light stimulus, participants 
stepped down on to the bottom force plates (leading with their test limb), paused to 
regain balance, then returned to the top plate. The return stepping data were not 
assessed.  
 
Data Processing: EMG and force plate data were synchronized via a 5V TTL 
pulse, generated by Spike2 software, and delivered with each light stimulus to both 
recording systems. Data were extracted from both recording systems and analysed 
using custom written Matlab software (R2017a). Force plate data were low pass 
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filtered at 20Hz using a second-order Butterworth filter. Onset of the anticipatory 
postural adjustment (APA) was detected manually from the center of pressure 
signal, for each trial for each participant, considering medial-lateral displacement 
only (Figure 1). The peak APA (i.e. peak medial-lateral displacement within 
approximately 500ms after onset of APA) was detected automatically, then manually 
checked for each trial. Center of pressure data were also used to determine the 
timing of the start and end of single-leg stance phase for the most painful (or 
dominant) leg i.e. timing of the first foot down relative to APA onset, and timing of 
the second foot down relative to APA onset.  
 
 
 
 
 
Insert Figure 1  
 
 
 
 
 
 
EMG data were bandpass filtered at 20-500Hz using a second-order 
Butterworth filter. EMG epochs of 10ms root-mean-squared were calculated over 
the length of the recording for each muscle. For each step, a threshold for a muscle 
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to be considered “active” was calculated as the mean+2 standard deviations of that 
recorded during quiet standing (Figure 1), from a 500ms window prior to APA onset. 
Epochs that exceeded this threshold during the stance phase of the painful limb 
were considered “active”. The “% muscle activation” ratio was calculated as the 
number of active epochs divided by the total number of epochs for the stance phase 
of the stepping tasks. 
 
Synchronisation between equipment was insufficient to enable analysis of 
EMG data from 5 individuals with PFOA and 5 control participants. As such, force 
plate data are reported from all participants in each group, and EMG data are 
reported from 17 people with PFOA, and 15 controls (Table 1). Force plate data were 
also analysed when considering only participants with synchronised EMG data, with 
results consistent with the total group (data not reported).   
 
Statistical Analysis: The distribution of data for each outcome measure was 
assessed for normality by group using Shapiro-Wilks test. To account for data that 
was not normally distributed, between-group comparisons were made using Mann-
Whitney U Tests. Significance was set at 0.05. Corrections for multiple comparisons 
were deliberately not made [14]. Instead, effect sizes for non-parametric data were 
calculated using the Mann-Whitney U statistic and the median difference between 
groups and interquartile ranges within groups presented. An online calculator 
(http://psychometrica.de/effect_size.html) was used to calculate Cohens d and the 
r statistic for between group effects from the Mann-Whitney U statistic. All other 
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analyses were run in SPSS v 25 (New York, USA). As data were not normally 
distributed, data are presented as median differences unless otherwise stated.  
 
Results: 
 
Twenty-two people with PFOA and 20 controls were recruited (see 
Supplementary Table 1 for demographics of the full cohort). For the EMG analyses 
(primary aim), 17 PFOA and 15 controls had sufficient data; participant 
characteristics are detailed in Table 2. The PFOA group consisted of 17 females, 
compared to 12 females in the control group. There were no differences between 
groups for age, height and weight. Based on the EQ-5D, 50% of the PFOA group 
reported difficulties performing usual activities compared to 0% in the control group, 
and 92% of the PFOA group reported general pain and discomfort compared to 8% in 
the control group. Note that the pain experienced by the control group was in a 
location other than their lower limb. The control group rated their overall health 
higher than those with PFOA (86% vs. 81%), and the PFOA group reported greater 
walking MET hours per week than the controls (Table 2).  
 
Force plate data: There were no differences in force plate data for center of 
pressure (CoP) or timing except for a 70ms (median difference) later peak Fz timing 
(the time between the light stimulus and the maximum force recorded in the Z plane 
i.e. the force perpendicular to the force plate) observed in the PFOA group during 
stair descent (d = 0.91, p = 0.01, see Table 3).  
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EMG data: Stair ascent: For the stepping leg, VL median onset was ~ 3ms earlier 
(median difference) at the initiation of stair ascent in the PFOA group (p<0.01, d = 
1.10, r: 0.48). During single leg stance on the top step, the PFOA group used GMax 
for a significantly shorter duration (median difference = 11%, p=0.05, d = 0.76, r = 
0.35). Stair descent: At initiation of stair descent, VL onset was 1ms earlier (d = 0.78, 
r = 0.36, p=0.04), and Sol onset 5ms earlier (d = 0.77, r = 0.36, p=0.04) in the PFOA 
group compared to controls (Table 4). During stance phase on the bottom step, 
there was a longer duration of VM and VL activation in the PFOA group (VM: median 
difference = 30%, d = 0.99, r = 0.45 p = 0.01; VL: median difference = 42%, d = 0.88, r 
= 0.40, p = 0.02). While not statistically significant (p = 0.12), LH activation duration 
was 19% shorter (median difference) in the PFOA group (d = 0.58, r = 0.28). 
Differences in muscle activation duration are represented in Figure 2.  
   
 
 
 
 
 
Figure 2 
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Table 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
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Table 4  
 
 
 
 
 
 
Discussion: 
 
This study compared neuromotor control of lower limb muscles during stair 
ambulation in people with PFOA and age matched healthy individuals. The PFOA 
group demonstrated different neuromotor strategies compared to controls. There 
are a number of potential explanations for these findings, including these strategies 
reflecting attempts to minimize knee pain on loading of the affected limb. However, 
as this is one of the first studies to explore neuromotor control in PFOA, there are 
few studies with which to compare our results.   
 
Both groups demonstrated similar timing and ground reactions forces during 
stair ambulation (Table 3). The only between-group difference in movement 
observed was a 70 ms later peak (Fz) force timing relative to APA onset in the PFOA 
group, compared to controls, when descending onto the most painful leg. This 
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meant that the peak Fz occurred ~60ms before the second foot touched down in the 
control group, and ~11ms after the second foot touched down in the PFOA group. 
The longer period between APA onset and peak Fz force, and the occurrence of peak 
Fz after the second foot touchdown in the PFOA group may reflect an attempt to 
reduce load on the painful limb i.e. they lightly loaded their painful side, then 
dropped heavily onto the non-painful side, during stair descent. This was the only 
between-group difference in the relative timing of movement.  
 
There were multiple between-group differences in EMG timing.  When 
comparing muscle onsets at the initiation of stair ascent, the PFOA group 
demonstrated an earlier onset of VL (3ms), and to a lesser non-significant extent, VM 
(4ms), as the most painful limb moved to step up onto the top step. Similarly, VL 
onset was also 1ms earlier in the PFOA group during stair descent. To the authors 
knowledge, there are no existing studies in isolated PFOA with which to compare our 
findings. However, we propose that there is likely to be very little clinical relevance 
of a 1-7ms difference in muscle onset timings between groups during stair descent 
[15], as this onset difference is well within the margin of error of this measure [15]. 
Further, a delay in EMG does not provide direct information about a delay in force 
production [15].  
 
The PFOA group did however demonstrate a significantly longer VL (42%) and 
VM (30%) activation duration during stair descent. This finding is similar to that 
observed by Childs et al [16] who found that individuals with mixed compartment 
knee OA have 1.5 times longer VL activation duration than controls during stair 
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descent. In PFOA, the quadriceps have been shown to be weaker [17] with smaller 
cross-sectional area [18], and generate less force during stair ambulation [9]. 
Therefore, the prolonged duration of activation of the quadriceps, in particular VL, 
during stair ambulation may relate to a need for greater activation of a muscle with 
reduced force generating capacity to match the same total muscle force produced. 
Considering the PFOA groups peak Fz during step descent occurred after touchdown 
of the second foot, prolonged quadriceps activation may reflect attempts to 
minimize anticipated painful knee flexion (kinesiophobia) upon weight acceptance.  
 
During stair ascent, GMax activation during stance phase on the top step was 
11% shorter in the PFOA group than the control group (d = 0.76). Previous studies 
have shown that individuals with PFOA have lower hip strength compared to healthy 
controls [19, 20] and utilize different pelvic and hip kinematics to ascend stairs [9]. 
However, it is uncertain whether the 11% reduction in GMax activation duration 
identified in the PFOA group is of a sufficient magnitude to impart any clinical 
impact. 
 
In the distal limb, a 5ms earlier onset of Sol in the PFOA group was observed 
in stair descent. Earlier activation of Sol may serve to stabilize anterior translation of 
the tibia upon initiation of knee flexion in preparation to step, possibly 
compensating for quadriceps weakness. However, as discussed above, the clinical 
significance of this difference is uncertain. 
 
Limitations  
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There are several limitations to this study. First, as this study is cross-
sectional in nature, we are unable to infer causality. Second, control participants 
were not imaged to confirm the absence of radiographic PFOA. However, clinical 
features alone are now considered sufficient for accurate diagnosis of knee OA [21] 
and control participants did not report any clinical signs or symptoms of PFOA. 
Kinematic measures were not available for this study, which limited our ability to 
determine joint forces. Future studies could benefit from combining kinematic, 
kinetic and EMG data utilizing a larger sample size to more fully describe altered 
strategies during stair ambulation and other similar pain inducing tasks such as sit to 
stand, in people with PFOA.  
 
It was not possible to explore muscle activation based on the severity of 
structural PFOA as either radiographic or MRI evidence of PFOA was accepted as 
inclusion criteria. Therefore, not all participants with PFOA had the same baseline 
imaging for categorization. While previous studies have not found an association 
with imaging severity and onset timing of the quadriceps in combined TF and PFOA 
[22], future larger scale studies may benefit from using the same imaging modality to 
determine if neuromotor control measures are related to radiographic or MRI grade 
of isolated PFOA. 
 
The findings of this study indicate that those with PFOA ascend and descend 
stairs with strategies that may be related to attempts to reduce knee flexion, or 
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result from reduced knee flexion. However, as kinematics were not recorded in this 
study, further research is required.  
 
Significance 
 This investigation demonstrated that people with PFOA descend stairs with 
increased quadriceps activation duration and a delay in peak force timing. These 
findings may represent attempts to minimize pain in the affected knee. Clinical 
strengthening interventions for the quadriceps and gluteals may be beneficial to 
assist with the observed neuromotor strategies. This requires investigation in future 
studies. 
 
Conclusions 
 
This is the first study to demonstrate that individuals with PFOA ascend and 
descend stairs with some different neuromotor control strategies compared to aged 
matched controls. During stair ascent, people with PFOA have an earlier onset of VL, 
and a shorter activation duration of GMax. During stair descent, earlier VL and Sol 
onset, and longer VL and VM activation duration in individuals with PFOA was 
observed. Strengthening interventions for the quadriceps and gluteals may support 
the observed neuromotor strategies and improve pain and function during stair 
ambulation in individuals with PF OA. 
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Figure 1. 
 
 
 
 
Figure 1. Force plate markings and starting positions for (A) stair ascent and (B) stair 
descent. (C) Example centre of pressure (COP) data collected from 1 participant 
during stair ascent. Timing of the light stimulus, onset of the anticipatory postural 
adjustment (APA), and timing of peak Medial/Lateral APA displacement is shown. 
Blue = COP displacement in Medial/Lateral direction; Red = Velocity of COP in 
Medial/Lateral direction which was used to assist in the determination of APA onset; 
Green = COP in Anterior/Posterior. Baseline muscle activity (EMG) was determined 
A: Start position for stair ascent 
descent  
C: Example COP data during a stair ascent 
trial  
B: Start position for stair 
descent  
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from the 50 ms prior to the light trigger which signalled to the participants to begin 
their movement. 
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Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Group mean differences in percentage of muscle activation duration, 
between people with PFOA (most painful side) and aged-matched controls. Data 
represents the single-leg stance period on the painful side (or matched leg for 
controls) during stair ascent (top), and during stair descent (bottom). Differences 
with an effect size d ≥ 0.50, which represents a medium effect size or greater, are 
represented by the green arrows. Movement of the non-painful side is represented 
by the black arrow. GMax: gluteus maximus; VL: vastus lateralis; VM: vastus 
medialis; LH: lateral hamstrings. 
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TABLE 1. Inclusion and exclusion criteria for the PF OA and control groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Inclusion Criteria Both Groups 
(i) aged ≥ 40 years;  
Exclusion Criteria Both Groups 
(i) current or previous pain in the knee, hip, lumbar spine or 
foot that had lasted longer than 3 months and/or required 
intervention;  
(ii) foot orthoses use in the last 12 months. 
(iii) a history of hip, knee or foot surgery;  
(iv) neurological or systemic arthritis conditions;  
(v) planned lower limb surgery in the following 2 months;  
(vi) physical inability to undertake testing procedures;  
(vii) an inability to understand written and spoken English. 
Specific Inclusion Criteria PF OA 
(i) anterior knee pain aggravated by at least two activities that 
load the PF joint (e.g. squatting, stair ambulation);  
(ii) pain during these activities present on most days in the past 
month;  
(iii) pain severity ≥ 30mm on a 100mm visual analogue scale 
during aggravating activities; 
(iv) radiographic (Kellgren and Lawrence ≥ grade 1 {Kellgren, 
1957 #463}), or MRI evidence of PF OA {Hunter, 2011 
#1065}. 
Specific Exclusion Criteria PF OA 
(i) concomitant pain from other knee structures (including the 
TF joint), hip or lumbar spine; recent treatment for PF pain 
(knee injections within the previous 3 months;  
(ii) foot orthoses or physiotherapy within the previous 12 
months) 
(iii) moderate to severe concomitant TF OA (Kellgren and 
Lawrence grade ≥ 3 on radiograph);  
(iv) contraindications to x-ray. 
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Table 2. Participant Demographics 
 
 Participant characteristics for EMG analysis 
Force plate analysis  PFOA: N=17 Control: 
N=15 
Difference P 
value 
95% CI 
Age years 59  10 57  10 1.9 0.59 -9 – 5 
Height m 1.67  8.64 1.71  10.80 -3.7 0.28 -3.31 – 10.75 
Weight kg 72.5  13.3 72.7  16.08 
-0.2 
0.97 
-10.61 – 
11.02 
Sex female (%) 
12/17 
(71%) 
8/15 (53%) 18%   
Right side tested 
(%)  
9/17 (53%) 9/15 (60%) -7%   
EQ-5D (% problems) 
Mobility 25% 0% 2%   
Self-care 0% 0% 0%   
Usual Activities 50% 0% 50%   
Pain & Discomfort 92% 8% 84%   
Anxiety & Depression 8% 0% 8%   
Best Imaginable 
Health % 
81.5  16.5 86.0  11.7 -4.5% 0.46 -8.5 – 17.8 
IPAQ 
Walk MET 3005  3435 1045  804 1960 0.06 -3980 – 60 
Moderate MET 813  906 600  630 213 0.48 -827 - 402 
Vigorous MET 1108  1432 1560  2068 -452 0.52 -967 - 1873 
Total MET 4926  3405 3131  2278 1795 0.12 -4075 - 485 
 
 
Data presented as mean  standard deviation unless otherwise noted, CI: confidence interval, MET: 
metabolic equivalent of task minutes, kg: kilograms, cm: centimeter.
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Table 3: Force Plate Data 
 
                                         Stair Ascent                                          Stair Decent 
Controls N=20 
Median IQR  
PFOA N=22 
Median IQR 
Median 
Diff. ES d 
P 
valu
e 
Controls N=20 
Median IQR 
PFOA N=23 
Median IQR  
Median 
Diff. ES d 
P 
value 
APA onset (ms) 0.73 0.68, 0.76 0.70 0.68, 0.78 0.03 0.16 0.60 0.73 0.70, 0.77 0.74 0.69, 0.81 0.00 0.20 0.51 
Peak APA (ms) 
0.91 0.86, 0.98 0.92 0.87, 1.02 -0.01 0 1.00 1.02 0.98, 1.11 1.06 0.98, 1.18 
-0.04 
0.19 
0.53 
1st Footdown 
(ms) 
1.91 1.80, 2.00 1.81 1.73, 1.93 0.10 0.45 0.15 2.00 1.83, 2.13 1.99 1.86, 2.19 0.01 0.1 0.75 
2nd Footdown 
(ms) 
2.88 2.80, 3.05 2.70 2.60, 2.98 0.18 0.49 0.12 2.81 2.66, 2.88 2.79 2.53, 2.99 
0.02 
0.007 
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Peak Fz (ms) 
3.12 1.94, 4.70 4.14 1.80, 4.96 
-1.02 
0.20 
0.51 2.20 1.74, 2.69 2.90 2.41, 4.04 
-0.70 
0.91* 
0.01* 
Peak Fz  (N) 
664 576, 865 679 593, 789 
-15.35 
0.12 
0.69 805 648, 939 787 658, 886 
17.34 
0.06 
0.85 
Size APA (mm) 12.99 8.36, 
19.31 
13.71 11.03-
17.58 
-0.72 
0.27 
0.39 
54.63 44.2- 
63.10 
57.60 45.07-64.91 
-2.97 
0.11 
0.71 
Phase 1: APA onset to 1st foot contact 
ML range 13.00 7.81, 
19.36 
13.71 11.44, 
17.61 
-0.71  
0.27 
0.39 
55.27 45.23-
63.10 
57.72 45.18, 
65.89 
-2.45 
0.15 
0.63 
AP range 
3.66 1.81, 5.13 3.39 2.44, 5.58 
0.27 0.13 0.67 
21.70 17.92-
28.19 
20.88 19.03, 
24.25 
0.82 0.1 0.75 
ML SD 
4.41 2.73, 6.95 4.71 4.09, 6.08 
-0.30 
0.28 
0.36 
20.33 16.22-
23.23 
21.72 16.66, 
23.97 
-1.40 
0.15 
0.63 
AP SD 1.06 0.60, 1.62 1.06 0.71, 1.73 0.00 0.16 0.61 7.87 6.07, 10.23 7.36 6.68, 8.79 0.51 0.13 0.68 
AC
CE
PT
ED
 M
AN
US
CR
IPT
27 
 
Path 
74.05 52, 103 73.62 67, 97 
0.43 0.24 0.45 201 171, 248 224 170, 266 
-23.35 
0.16 
0.61 
Phase 2: 1st foot contact to 2nd foot contact 
ML range 
22.25 16.71, 
30.01 
21.34 15.90, 
28.07 
0.92 0.09 0.76 
120.15 95.65-
143.6 
109.23 96.19-
136.22 
10.91 
0.27 
0.38 
AP range 
79.48 70.05, 
96.95 
87.61 9.06, 
99.39 
-8.13 
0.46 
0.14 29.96 20.42-9.21 
44.01 24.66, 
57.37 
-14.05 
0.33 
0.28 
ML SD 
5.20 4.20, 6.67 5.28 4.03, 6.72 
-0.07 
0.05 
0.86 
33.12 27.21-
40.63 
30.37 25.36, 
36.87 
2.75 0.39 0.21 
AP SD 
18.29 15.45, 
23.46 
20.79 8.20, 
23.51 
-2.50 
0.45 
0.16 8.02 4.89, 8.73 6.98 4.90, 9.28 1.04 0.03 0.92 
Path 163 134, 257 192 160, 24 
-28.43 
0.37 
0.24 225 195, 256 238 186, 291 
-12.68 
0.23 
0.45 
 
IQR: interquartile range; Diff.: difference; ES: effect size; APA: anticipatory postural adjustment; ms: milliseconds; ML: medial to lateral; AP: anterior to posterior, SD: 
standard deviation. All timings are presented relative to APA onset. 
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Table 4. EMG Onset and Activation Duration of The Stepping Leg During Stair Ambulation 
 Stair Ascent Stair Descent 
Controls PFOA 
Median 
Difference 
P 
value 
Controls PFOA 
Median 
Difference 
P  
value 
Median (IQR) ES (d, r) Median (IQR) ES (d, r) 
Muscle Onset Timing, relative to APA onset (ms) 
GMax 0.04  
(0.03, 0.18) 
0.05 
 (0.03, 0.11) 
-0.01 
(0.007, 0) 
0.98 
0.10 
(0.05, 0.17) 
0.06 
(0.04, 0.10) 
0.04 
(0.43, 0.21) 
0.25 
GMed 0.03  
(0.02, 0.08) 
0.04  
(0.03, 0.08) 
-0.01 
(0.41, 0.2) 
0.28 
0.04 
(0.02, 0.07) 
0.04 
(0.02 ,0.07) 
0.00 
(0.22, 0.11) 
0.55 
MH 0.09  
(0.06, 0.19) 
0.11 
 (0.07, 0.13) 
-0.02 
(0.07, 0.03) 
0.86 
0.15 
(0.10, 0.27) 
0.14 
(0.09, 0.25) 
0.01 
(0.20, 0.09) 
0.60 
LH 0.09  
(0.08, 0.15) 
0.12  
(0.08, 0.19) 
-0.03 
(0.23, 0.11) 
0.54 
0.14 
(0.10, 0.34) 
0.16 
(0.07, 0.25) 
-0.02 
(0.07, 0.03) 
0.85 
VM 0.12  
(0.05, 0.17) 
0.07  
(0.04, 0.11) 
0.05 
(0.51, 0.25) 
0.17 
0.08 
(0.04, 0.10) 
0.05 
(0.04, 0.11) 
0.03 
(0.007, 0) 
1 
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VL 0.07  
(0.05, 0.16) 
0.04 
 (0.03, 0.06) 
0.03 
(1.1, 0.48) 
<0.01* 
0.06 
(0.04, 0.17) 
0.05 
(0.02, 0.07) 
0.01 
(0.78, 0.36) 
0.04* 
MG 0.08 
(0.06, 0.13) 
0.08  
(0.06, 0.16) 
-0.01 
(0.29, 0.14) 
0.45 
0.18 
(0.10, 0.28) 
0.16 
(0.11, 0.24) 
0.02 
(0.17, 0.08) 
0.65 
LG 0.07  
(0.05, 0.11) 
0.07  
(0.05, 0.13) 
0.00 
(0.13, 0.06) 
0.74 
0.16 
(0.11, 0.22) 
0.12 
(0.08, 0.19) 
0.05 
(0.29, 0.14) 
0.43 
Sol 0.08  
(0.06, 0.11) 
0.08  
(0.06, 0.12) 
0.00 
(0.04, 0) 
0.92 
0.19 
(0.15, 0.24) 
0.15 
(0.10, 0.18) 
0.05 
(0.77, 0.36) 
0.04* 
Duration of Muscle Activation, % of stance phase duration 
GMax 0.77  
(0.71, 0.84) 
0.66  
(0.55, 0.76) 
0.11 
(0.76, 0.35) 
0.05* 
0.66 
(0.41, 0.79) 
0.64 
(0.50, 0.79) 
0.02 
(0.03, 0) 
0.94 
GMed 0.79  
(0.70, 0.83) 
0.75  
(0.63, 0.81) 
0.04 
(0.44, 0.21) 
0.25 
0.74 
(0.48, 0.79) 
0.77 
(0.67, 0.81) 
-0.03 
(0.33, 0.16) 
0.37 
MH 0.71  
(0.41, 0.94) 
0.77  
(0.50, 0.87) 
-0.06 
(0.09, 0.04) 
0.83 
0.70 
(0.52, 0.84) 
0.64 
(0.37, 0.80) 
0.06 
(0.42, 0.20) 
0.26 
LH 0.70  
(0.45, 0.91) 
0.57  
(0.25, 0.79) 
0.14 
(0.50, 0.24) 
0.19 
0.58 
(0.40, 0.70) 
0.40 
(0.21, 0.57) 
0.19 
(0.58, 0.28) 
0.12 
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VM 0.87  
(0.69, 0.95) 
0.88  
(0.81, 0.92) 
0.00 
(0.07, 0.03) 
0.86 
0.53 
(0.40, 0.65) 
0.83 
(0.70, 0.89) 
-0.30 
(0.99, 0.44) 
0.01* 
VL 0.84 
(0.62, 0.99) 
0.85  
(0.71, 0.93) 
-0.01 
(0.06, 0.03) 
0.89 
0.41 
(0.27, 0.83) 
0.83 
(0.59, 0.95) 
-0.42 
(0.88, 0.40) 
0.02* 
MG 0.28  
(0.18, 0.41) 
0.36  
(0.18, 0.47) 
-0.08 
(0.26, 0.13) 
0.49 
0.63 
(0.45, 0.80) 
0.57 
(0.43, 0.65) 
0.06 
(0.47, 0.23) 
0.20 
LG 0.38  
(0.24, 0.53) 
0.39  
(0.30, 0.56) 
-0.01 
(0.03, 0) 
0.95 
0.68 
(0.53, 0.73) 
0.63 
(0.49, 0.70) 
0.05 
(0.25, 0.12) 
0.50 
Sol 0.24  
(0.20, 0.38) 
0.29  
(0.19, 0.40) 
-0.05 
(0.26, 0.13) 
0.49 
0.33 
(0.17, 0.47) 
0.33 
(0.24, 0.46) 
0.00 
(0.11, 0.05) 
0.77 
 
IQR: interquartile range; ES: effect size; ms: milliseconds; GMax: gluteus maximus; GMed: gluteus medius; MH: medial hamstrings; LH: lateral hamstrings; VM: vastus 
medialis; VL: vastus lateralis; MG: medial gastrocnemius; LG: lateral gastrocnemius; Sol: soleus.  
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